Results 81 to 90 of about 1,663 (174)
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer
World Journal of Clinical Oncology, 2014 Ziv-afilbercept (Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor (VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG1. Recently, a randomized, open-label, phase III study compared 5-fluorouracil, leucovorin, irinotecan (FOLFIRI)/Ziv with FOLFIRI ...
Muhammad Wasif Saif
openalex +4 more sources
A hypothetical therapeutic effect of light peripheral panretinal photocoagulation in neovascular age-related macular degeneration [PDF]
, 2022 Background: Vascular endothelial growth factor (VEGF) is a significant modulator of ocular angiogenesis, including that of neovascular age-related macular degeneration (nAMD).
Mansour, Ahmad M +2 more
core +2 more sources
Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes
Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020 Purpose. To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea®; Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. Methods. Forty New Zealand albino rabbits were recruited to the study and were divided into four groups to be sacrificed at ...
Alireza Lashay +13 more
wiley +1 more source
Frontiers in Oncology, 2023 ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi +6 more
doaj +1 more source
Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report [PDF]
Kosin Medical Journal, 2023 Drug-induced immune thrombocytopenia (DITP) is a very rare disease, with an estimated annual incidence of 10 cases per million. Oxaliplatin and irinotecan are widely used as chemotherapy for high-risk stage II and III colorectal cancer, and DITP has been
Minna Kim, Jong Hoon Lee, Jong Yoon Lee
doaj +1 more source
Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020 Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods. The following groups of New Zealand white rabbits received conbercept injections (0.5 mg/0.05 ml): a subretinal group (subretinal injection in vitrectomized eyes ...
Teng-teng Yao +7 more
wiley +1 more source
Ziv-aflibercept use in metastatic colorectal cancer.
J Adv Pract Oncol, 2013 Rodriguez M.
europepmc +4 more sources
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review [PDF]
, 2022 Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such treatments may be relatively more expensive compared to small molecule therapies.
Ebbers, Hans C +5 more
core +2 more sources
The Oncologist, Volume 25, Issue 1, Page e75-e84, January 2020., 2020 Abstract Background Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). This study assesses adherence and duration of therapy with FTD + TPI versus REG and explores the effect of sequencing on adherence. Materials and Methods Adults diagnosed with mCRC
Anuj K. Patel +6 more
wiley +1 more source